Sibutramine: Myths and Realities
https://doi.org/10.14341/omet2014412-17
Abstract
The paper presents data from competent drug controlling agencies form Russia, United States, Europe and other regions, comments on the main serious misconceptions of sibutramine-containing medicines, discusses the prerequisites for the analysis of the situation with sibutramine that initiated a SCOUT study, analyzes the history of sibutramine-containing drug Meridia. The results of observational research programs carried out in Russia (completed – "VESNA" and continued – "Primavera") are discussed in relation to the efficacy and safety of sibutramine-containing drug Reduxine for the target audience patients.
About the Authors
Marina Olegovna Galieva
Endocrinology Research Centre, Moscow
Russian Federation
MD postgraduate student
Russian Federation
MD postgraduate student
Ekaterina Vladimirovna Ershova
Endocrinology Research Centre, Moscow
Russian Federation
Research fellow
Russian Federation
Research fellow
Ksenya Andreevna Komshilova
Endocrinology Research Centre, Moscow
Russian Federation
Research fellow
Russian Federation
Research fellow
References
1. Clinicaltrials. A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese. Patients (SCOUT). Last updated April;17.
2. Curfman GD, Morrissey S, Drazen JM. Sibutramine – Another Flawed Diet Pill. N Engl J Med 2010;363(10):972–974. doi: 10.1056/NEJMe1007993.
3. James, W. Philip T, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, et al. Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects. N Engl J Med 2010;363(10):905–917. PMID: 20818901.
4. Seimon RV, Edpinoza D, Ivers L, Gebski V, Finer N, Legler UF, et al. Caterson ID. Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease. International Journal of Obesity. 2014;10(9):1165–1171. PMID: 24406481. doi: 10.1038/ijo.2014.2.
5. Caterson ID, Finer N, Coutinho W, Gaal, L.F. Van, Maggioni AP, Torp-Pedersen C, et al. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes, Obesity and Metabolism 2012;14(6):523–530. PMID: 22192338. doi: 10.1111/j.1463-1326.2011.01554.x.
6. Аметов А.С. Отчет о программе ВЕСНА. Эффективное лечение ожирения – путь борьбы с эпидемией Diabetes mellipidus. // Эффективная фармакотерапия. Эндокринология. Спецвыпуск. – 2013; – С. 7–11. [Ametov AS. Report about the VESNA program. Effective treatment of obesity – the way to combat the epidemic of diabetes mellipidus. Effektivnaya farmakoterapiya. Endokrinologiya. Spetsvypusk. 2013; 7–11.].
7. Мельниченко Г.А., Романцова Т.И., Журавлева М.В. Всероссийская программа безопасного снижения веса «ПримаВера». Итоги первого года проведения. // Ожирение и метаболизм. – 2014; – №1. – С. 62–67. [Melnichenko GA, Romantsova TI, Zhuravleva MV. Vserossiyskaya programma bezopasnogo snizheniya vesa «PrimaVera». Itogi pervogo goda provedeniya. Obesity and metabolism. 2014; 1: 62–67.].
8. Pavlik V, Fajfrova J, Slovacek L, Drahokoupilova E. The role of sibutramine in weight reduction. Bratisl Lek Listy 2013;114(3):155–157. PMID: 23406184. doi: 10.4149/BLL_2013_034.
Review
For citations:
Galieva M.O., Ershova E.V., Komshilova K.A. Sibutramine: Myths and Realities. Obesity and metabolism. 2014;11(4):12-17. (In Russ.) https://doi.org/10.14341/omet2014412-17
Views:
1616
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
